Vera Therapeutics, Inc.
Vera Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing therapies for serious immunological diseases. Its pipeline includes atacicept, MAU868, and VT-109, with development, manufacturing, and eventual commercialization supported through third-party partners and contract manufacturing organizations.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueAtacicept is the company's lead immunology asset being developed for IgAN and other potential indications.
MAU868 and VT-109 represent additional biologic programs in earlier stages of development.
Internal R&D, clinical operations, and regulatory work to advance product candidates through trials.
Sales, medical affairs, market access, and distribution capabilities for approved products.
Customers
Vera Therapeutics does not yet sell approved products, so its near-term 'customers' are primarily clinical trial investigators, patients enrolled in studies, regulators, and future payors and physicians for any approved therapy. The commercial opportunity described in filings centers on nephrologists, patients with IgAN, and healthcare systems that would adopt a disease-modifying immunology treatment.
Patients enrolled in studies for atacicept, MAU868, and VT-109 to generate safety and efficacy data.
Specialist physicians expected to prescribe atacicept if approved for IgAN and related kidney disease.
FDA, EMA, and other agencies that assess clinical, manufacturing, and labeling packages.
Public and private payors that determine reimbursement and patient access for approved therapies.
Channel partners that would support access and distribution after commercialization.
Strategy
Vera Therapeutics is focused on advancing atacicept toward commercialization while continuing to develop MAU868 and VT-109. The company is building specialty commercial capabilities around IgAN, while relying on outsourced manufacturing and external partners to keep the operating model asset-light.
The lead asset is the main path to first product revenue and defines the company's near-term value creation.
Successful trial outcomes are required to support approval and future label expansion.
A focused nephrology commercial model is needed to reach specialist prescribers and secure reimbursement.
Additional programs and collaborations can diversify scientific risk and extend the platform.
Geography
The company is headquartered in Brisbane, California and operates as a U.S.-based biotechnology developer. Its lead commercial planning is centered on the United States, with additional market opportunity discussed for Europe and Japan for IgAN, and any ex-U.S. commercialization may involve collaborations.
Risks
The company is exposed to typical biotech risks: clinical failure, regulatory delay, manufacturing dependence, and uncertainty around physician adoption and reimbursement. Because it has no approved products, its business model depends on successful development of a small number of assets and on access to external capital until commercialization.
- Clinical development failureImpact: CriticalLikelihood: Medium
The company has a limited number of product candidates, so negative trial data could materially reduce future prospects.
Exposure - Capital needs and dilutionImpact: HighLikelihood: High
Development-stage biotech companies often require external financing before product sales begin.
Exposure - Regulatory approval riskImpact: HighLikelihood: Medium
Even positive clinical data may not translate into approval if safety, efficacy, or CMC packages are insufficient.
Exposure - Manufacturing and supply chain dependenceImpact: HighLikelihood: Medium
The company relies on contract manufacturers for clinical and future commercial supply, which can affect quality and timing.
Exposure: cGMP biologics production
- Commercial adoption and reimbursementImpact: HighLikelihood: Medium
Specialist prescribing and payer coverage will determine whether an approved therapy gains meaningful uptake.
Exposure: IgAN market access
Accounting
Judgemental itemsClinical and manufacturing vendors are often billed after services are performed, so estimates affect expenses and liabilities.
Impact: Can shift quarterly operating expense recognition
Biotech companies often use equity awards to attract talent, affecting reported operating costs.
Impact: Impacts R&D and G&A expense
The company holds a large cash balance and marketable securities portfolio that must be classified and measured appropriately.
Impact: Affects liquidity presentation and interest income
Any partnering arrangements could create deferred revenue, milestone accounting, or variable consideration judgments.
Impact: Could materially affect revenue recognition timing
Similar listed companies
Publicly listed companies with a comparable business focus.
Vir Biotechnology, Inc.
VIR · Biological Products, (No Diagnostic Substances)
BriaCell Therapeutics Corp.
BCTXZ · Pharmaceutical Preparations
Crispr Therapeutics AG
CRSP · Biological Products, (No Diagnostic Substances)
CRISPR Therapeutics AG is a gene-editing biopharmaceutical company built around CRISPR/Cas9 technology and the development of gene-based medicines for serious diseases.
Vor Biopharma Inc.
VOR · Biological Products, (No Diagnostic Substances)
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Metagenomi Therapeutics, Inc.
MGX · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026